New Daily Pill Rivals Injections in Lowering Cholesterol, Offering Hope for Heart Disease Prevention
A new experimental daily pill, enlicitide, has demonstrated significant cholesterol-lowering effects in a large clinical trial, potentially offering a more convenient alternative to injectable therapies for individuals at high risk of heart disease and stroke. The medication reduced “disappointing” LDL cholesterol levels by up to 60%, according to research presented at the American Heart Association’s Scientific Sessions 2025 and published in the New England Journal of Medicine.
The Challenge of High Cholesterol and Current Treatments
High LDL cholesterol plays a central role in the development of cardiovascular disease. LDL cholesterol can accumulate within the walls of blood vessels, forming plaques that narrow arteries and increase the risk of heart attacks and strokes. While statins are widely used to lower cholesterol, many patients still don’t reach recommended target levels 1.
Existing highly effective treatments, such as PCSK9 inhibitors (evolocumab and alirocumab), have historically been administered via injection, which can be a barrier to widespread adoption. Research indicates that these injectable medications are often underprescribed, potentially due to cost, insurance coverage, and patient preference for oral medications 1.
How Enlicitide Works
Enlicitide is a PCSK9 inhibitor, meaning it works by limiting the activity of the PCSK9 protein. This protein interferes with the liver’s ability to remove LDL cholesterol from the bloodstream. By blocking PCSK9, enlicitide helps the liver clear LDL cholesterol more effectively 2.
Unlike previous PCSK9 inhibitors, enlicitide is administered as a once-daily oral pill, offering a potentially more convenient option for patients.
Clinical Trial Results
A phase 3 clinical trial involving 2,909 patients with atherosclerosis or at high risk for cardiovascular disease demonstrated enlicitide’s effectiveness. Participants who received enlicitide experienced an average LDL cholesterol reduction of approximately 60% compared to those who received a placebo 1. Most participants were already taking statin medications, but still had elevated LDL cholesterol levels (96 mg/dL), well above the recommended target of 70 mg/dL for those with atherosclerosis and 55 mg/dL for those at elevated cardiovascular risk.
In addition to lowering LDL cholesterol, enlicitide also reduced other blood markers associated with cardiovascular risk, including non-HDL lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a). These improvements were sustained throughout a one-year follow-up period 1.
Future Directions
Researchers are currently conducting a further clinical trial to determine whether the significant reductions in LDL cholesterol achieved with enlicitide translate into a reduced risk of heart attacks and strokes. If approved by the Food and Drug Administration, enlicitide could represent a significant advancement in the prevention and treatment of cardiovascular disease.
Key Takeaways
- Enlicitide is an investigational oral PCSK9 inhibitor that significantly lowers LDL cholesterol.
- In a phase 3 trial, enlicitide reduced LDL cholesterol by up to 60%.
- The drug offers a potentially more convenient alternative to injectable PCSK9 inhibitors.
- Ongoing research is evaluating whether enlicitide can reduce the risk of heart attacks and strokes.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. It is essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
References:
- American Heart Association. Investigational daily pill lowered bad cholesterol as much as injectables.
- Times Now. Breakthrough Cholesterol Pill Cuts LDL by 60%; Could It Prevent Heart Attacks?